With Ton Van Daelen, Portfolio Lead, Scientific Informatics, BIOVIA
It typically takes about 5 years and requires the synthesis of 4,000 or more compounds to develop a new lead candidate. BIOVIA Dassault Systèmes has launched an initiative that leverages AI and machine learning techniques to significantly reduce cost and timelines for discovering new lead candidates while at the same time to increase their success rate in the clinic.
BIOVIA’s Generative Therapeutics Design solution (GTD) helps medicinal chemists decide ‘what to make next’ in an active learning process. The solution combines advanced predictive modeling techniques with automated structure generation, modeling and simulation, and multi-objective optimization. Computational chemists can play an important supporting role integrating in house methods and tailoring these to the needs of the end-user. In this webinar, BIOVIA will present the GTD solution and discuss various customer projects.